# Echo Neurotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/echo-neurotechnologies

- Industry: Healthcare
- Headquarters: San Francisco, US
- Website: www.echo.bio
- Total disclosed funding: $50M
- Latest round: Series A (Jan 31, 2025)
- Investors on record: 1

## About

Founded in 2023 and based in California, US, Echo Neurotechnologies Corp. operates as a health-tech company offering neurotechnology designed to interpret neural signals for various applications. In January 2025, Echo Neurotechnologies Corp. raised USD 50 million in venture funding from investor Andreessen Horowitz. 

Echo Neurotechnologies specializes in advanced neurotechnological solutions designed to decode brain activity and enhance human capabilities. The company’s core offerings include innovative hardware and software platforms that utilize sophisticated algorithms to interpret neural signals. These products are aimed at addressing a range of end-use cases, including neurorehabilitation, cognitive enhancement, and mental health therapies. Echo Neurotechnologies serves a diverse client base, including healthcare providers, research institutions, and technology developers, with end users encompassing patients seeking cognitive recovery and professionals aiming to leverage brain data for improved outcomes. The company operates in key geographical markets including North America, Europe, and parts of Asia, which facilitates its outreach to a global audience in sectors such as medicine, education, and wellness.

Echo Neurotechnologies generates revenue through a combination of subscription-based models and direct sales of its proprietary neurotechnology products. The company engages in B2B transactions with healthcare providers and research organizations, allowing these clients to incorporate Echo’s technologies into their services and studies.

The company plans to utilize the January 2025 funding to develop its healthcare platform and support research and development. The company has plans to launch new products designed for healthcare applications and aims to expand its reach into new geographic markets, particularly targeting Europe and Asia, by the end of 2025.

## Funding rounds

- Series A, Jan 31, 2025, $50M — Andreessen Horowitz

## Investors

- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series A